✉news ScienceBiology first seen 3 d ago, last 3 d ago, peak #14
Kazia to Present Paxalisib Breast Cancer Research in San Antonio
Original: Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
Kazia Therapeutics says two abstracts on paxalisib research into tumor and immune reprogramming have been accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium, a leading venue for breast cancer science. The company is developing paxalisib, a brain-penetrant PI3K/mTOR inhibitor, and the accepted work suggests it is extending the drug's development into breast cancer beyond its earlier focus on brain tumors.
Why now: Investors and oncology watchers follow any signal that paxalisib is expanding into a major new cancer indication.
Kazia TherapeuticsPaxalisibSan Antonio Breast Cancer Symposium
Evidence
- Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium · The Malaysian Reserve
API: https://socialmediatrends-api.osmike.com/v1/trends/4630352